- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04371081
Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance
June 6, 2023 updated by: Abbott Medical Devices
The purpose of this post-marketing clinical use database surveillance is to observe the frequency, type, and degree of adverse device effects and adverse events in order to assure the safety of the medical device, and to collect safety and efficacy information for evaluating the results of its clinical use.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The Surveillance will be conducted per the standards required by the Ministry of Health, Labour and Welfare (MHLW) and in the standards for post-marketing surveillances and studies [except for those defined in the Ministerial Ordinance on Good Clinical Practice for Medical Devices (MHLW Ordinance No. 36, 2005)] based on Paragraph 4, Article 23-2-9 (including application mutatis mutandis per Article 23-2-19 of Revised PAL) of the Law on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices, etc. (Law No. 145, 1960, hereinafter referred to as "Revised PAL") by the Marketing Authorization Holder or accredited foreign manufacturer of a medical device defined in Paragraph 1, Article 23-2-5 of Revised PAL.
Study Type
Observational
Enrollment (Estimated)
70
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yuri Masui
- Phone Number: 1799 +81-3-3524-1792
- Email: yuri.masui@abbott.com
Study Locations
-
-
-
Tokyo, Japan
- Recruiting
- Showa University Hospital
-
Contact:
- Hideshi Tomita, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 days and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
All patients with patent ductus arteriosus (PDA) in whom an Amplatzer™ Piccolo Occluder (Piccolo) implant was attempted will be included in this registry.
Description
Inclusion Criteria:
The device is used to percutaneously close the PDA of a patient who meets all of the following:
- PDA ≤4 mm in diameter
- PDA ≥3 mm in length
- Weight ≥700 g
Exclusion Criteria:
- Age <3 days
- Coarctation of the aorta
- Left pulmonary artery stenosis
- Cardiac output that is dependent on right to left shunt through the PDA due to pulmonary hypertension
- Thrombus in the implant site, or sign of venous thrombus in a vessel in which the occluder is inserted and delivered
- Endocarditis, or infection that can cause bacteremia
- Allergic or potentially allergic to nickel
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Amplatzer Piccolo Occluder
Amplatzer Piccolo Occluder device implant
|
Interventional placement of vascular occluder
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The rate of major complications through 180 days after an attempted Piccolo device implant
Time Frame: Through 180 days after an attempted Piccolo device implant
|
Through 180 days after an attempted Piccolo device implant
|
The rate of effective closure of the ductus arteriosus among subjects with a successful Piccolo implant as assessed by the presence of either a Grade 0 or Grade 1 shunt at the 6-month follow-up by transthoracic echocardiography
Time Frame: At the 6-month follow-up
|
At the 6-month follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2020
Primary Completion (Estimated)
November 30, 2024
Study Completion (Estimated)
May 31, 2025
Study Registration Dates
First Submitted
April 28, 2020
First Submitted That Met QC Criteria
April 29, 2020
First Posted (Actual)
May 1, 2020
Study Record Updates
Last Update Posted (Actual)
June 7, 2023
Last Update Submitted That Met QC Criteria
June 6, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABT-CIP-10290
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patent Ductus Arteriosus
-
PFM Medical, IncBright Research PartnersCompleted
-
Abbott Medical DevicesCompletedPatent Ductus Arteriosus (PDA)United States
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaCompletedPatent Ductus Arteriosus | Patent Ductus Arteriosus After Premature Birth | Patent Ductus Arteriosus - Delayed ClosureItaly, United Kingdom
-
Nada YoussefCompletedPatent Ductus Arteriosus After Premature Birth | Patent Ductus Arteriosus Conservative ManagementEgypt
-
Ankara UniversityCompletedPatent Ductus Arteriosus in Preterm InfantsTurkey
-
Abbott Medical DevicesNo longer availablePatent | Ductus | Arteriosus
-
University of FlorenceCompletedDuctus Arteriosus, PatentItaly
-
National Taiwan University HospitalCompletedPatent Ductus Arteriosus
-
Rambam Health Care CampusCompletedDuctus Arteriosus, PatentIsrael
-
Soha mahmoud Hussien mahdyAssiut UniversityNot yet recruiting
Clinical Trials on Amplatzer Piccolo Occluder
-
Abbott Medical DevicesActive, not recruitingPFO - Patent Foramen OvaleJapan
-
Abbott Medical DevicesRecruitingPFO - Patent Foramen Ovale | VSD - Muscular Ventricular Septal Defect | PIVSD - Post Infarct Muscular Ventricular Septal Defect | ASD - Atrial Septal DefectSpain, Germany, Poland, France, Italy, Netherlands, Switzerland
-
Abbott Medical DevicesTerminatedAtrial Septal Defect SecundumUnited States
-
Abbott Medical DevicesCompletedMembranous Ventricular Septal DefectsUnited States
-
Abbott Medical DevicesCompletedAtrial Septal DefectUnited States
-
Abbott Medical DevicesCompleted
-
Abbott Medical DevicesTerminatedMigraine | Patent Foramen Ovale | Migraine With Aura | PFOUnited Kingdom, Germany, Canada, Switzerland
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedAortic Valve StenosisUnited States
-
Abbott Medical DevicesRecruitingStroke | Patent Foramen OvaleUnited States, Germany, Canada, Switzerland, Italy, Portugal, United Kingdom
-
Abbott Medical DevicesCompleted